AngioDynamics Inc (ANGO) stock
Close on Nov 11, 2026Market cap $522.32MP/E –Yield –
AngioDynamics Inc grew revenue 8.2% to $325.38M over the twelve months to Aug 31, 2026. Free cash flow was $1.44M. At the latest close the market valued the company at $522.32M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Aug 31, 2026
Valuation
- Market cap
- $522.32M
- P/E ratio
- –
- Price to sales
- 1.61
- Price to book
- 3.19
- Dividend yield
- –
- Free cash flow yield
- 0.28%
Fundamentals
- Revenue
- $325.38M
- Net income
- -$32.94M
- EPS, diluted
- -$0.78
- Free cash flow
- $1.44M
- Book value per share
- $3.90
- Diluted shares
- 42M
Trading
- Next earnings
- Jan 5, 2027 (estimated, before the open)
- Previous close
- $12.07
- Open
- $12.15
- Day's range
- $12.06 – $12.43
- Volume
- 441,400
- Average volume (20 days)
- 682,059
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 0.34
- 52-week range
- $9.39 – $16.29
- RSI (14 days)
- 49.5
- Volatility (1 year)
- 48.3%
- Relative volume
- 0.71×
- WACC
- 7.4%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ANGO | S&P 500 | Difference | ANGO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +7.8% | -2.4% | +10.2 pts | ||
| 3 months | -21.1% | -1.2% | −20.0 pts | ||
| Year to date | -3.3% | +12.3% | −15.6 pts | ||
| 1 year | -1.5% | +12.4% | −14.0 pts | ||
| 3 years | +100.0% | +78.8% | +21.2 pts | +26.0% | +21.4% |
| 5 years | -58.0% | +75.2% | −133.1 pts | -15.9% | +11.9% |
| 10 years | -26.5% | +311.1% | −337.6 pts | -3.0% | +15.2% |
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases AngioDynamics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About AngioDynamics
Surgical & Medical Instruments & Apparatus
AngioDynamics designs, manufactures, and markets medical devices and technologies used to treat cardiovascular disease and cancer. The company operates through two main business segments: Med Tech and Med Device. Its product portfolio includes atherectomy systems, mechanical thrombectomy and venous drainage devices, thrombolytic catheters, irreversible electroporation and microwave tissue ablation platforms, angiographic catheters, guidewires, drainage catheters, micropuncture kits, and implantable ports. Its target customers and end users include interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses.
Company profile, executives and historyAngioDynamics stock: common questions
What is AngioDynamics's stock price?
ANGO closed at $12.42 on Nov 11, 2026, up 2.90% on the day. Over the past 52 weeks it traded between $9.39 and $16.29.
What is AngioDynamics's market cap?
AngioDynamics was worth $522.32M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ANGO's P/E ratio?
AngioDynamics lost money over the twelve months to Aug 31, 2026 (diluted EPS -$0.78), so it has no meaningful P/E ratio.
How much revenue does AngioDynamics make?
AngioDynamics reported revenue of $325.38M for the twelve months to Aug 31, 2026, up 8.2% from a year earlier.
Does AngioDynamics pay a dividend?
No. AngioDynamics has not paid a cash dividend over the last twelve months.
When does AngioDynamics report earnings next?
AngioDynamics is expected to report Q2 FY2027 results on Jan 5, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ANGO stock performed over the past year?
Including dividends, ANGO returned -1.5% over the past year, against +12.4% for the S&P 500.
How many ANGO shares are sold short?
2M shares were sold short at the latest FINRA report, 5.06% of the float, or 2.9 days of average trading volume.
Who are AngioDynamics's competitors?
Companies most similar to AngioDynamics by business, industry and size include LMAT, AORT, ATRC, DCTH, ARAY.
See a number that looks wrong?